Exhibit 99.1 Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update -Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024- -Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non- Clinical Comparability, A Major Milestone on Path to CMC Clearance for BLA- -Received First Milestone Payment of $10 Million under U.S. Distribution and Commercializatio ...